江蘇寧滬高速公路(00177.HK)擬發行不超80億元公司債券
格隆匯12月23日丨江蘇寧滬高速公路(00177.HK)公佈,於2019年12月23日,公司第九屆董事會第十四次會議審議並批准《關於本公司公開發行公司債券的議案》,同意公司公開發行不超過人民幣80億元公司債券,授權董事孫悉斌先生在註冊有效期內處理合同簽署及資金撥付審批等後續相關事項,並將此議案提請股東大會審議。
審議並批准《關於設立香港子公司及參與組建聯合體共同收購土耳其ICA項目的議案》。同意公司出資不超過1.3億美元在中華人民共和國香港特別行政區設立全資子公司江蘇寧滬國際(香港)有限公司,將其作為公司參與中資聯合體收購境外資產的平台,並授權孫悉斌先生及姚永嘉先生處理後續相關事宜。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.